PharmacoEconomics

Rationing of Drugs for Rare Diseases
pp. 315-316(2)
Author: Hughes, Dyfrig

Bernard S. Bloom, PhD
pp. 317-318(2)
Author: Glick, Henry A.

The Burden of Age-Related Macular Degeneration
pp. 319-334(16)
Authors: Schmier, Jordana K.; Jones, Mechelle L.; Halpern, Michael T.

Economic and Developmental Considerations for Pharmacogenomic Technology
pp. 335-343(9)
Authors: Vernon, John A.; Johnson, Scott J.; Hughen, W. Keener; Trujillo, Antonio

Optimal Assignment of Treatments to Health States Using a Markov Decision Model: An Introduction to Basic Concepts
pp. 345-354(10)
Authors: Bala, Mohan V.; Mauskopf, Josephine A.

Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment: A Review and Consolidation of Quality Assessment
pp. 355-371(17)
Authors: Philips, Zoë; Bojke, Laura; Sculpher, Mark; Claxton, Karl; Golder, Su

Post-Exposure Influenza Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the UK
pp. 373-386(14)
Authors: Sander, Beate; Hayden, Frederick G.; Gyldmark, Marlene; Garrison, Louis P.

A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy
pp. 387-400(14)
Authors: Anis, Aslam H.; Sun, Huiying; Singh, Sonia; Woolcott, John; Nosyk, Bohdan; Brisson, Marc

Productivity Costs in Health-State Valuations: Does Explicit Instruction Matter?
pp. 401-414(14)
Authors: Krol, Marieke; Brouwer, Werner; Sendi, Pedram

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women
pp. 415-416(2)
Author: Land, Stephanie

The Authors' Reply
pp. 416-417(2)
Authors: Milne, Richard J.; Heaton-Brown, Kathy H.; Hansen, Paul; Thomas, David; Harvey, Vernon; Cubitt, Alison